Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2

American Heart Journal

Volumn 158, Issue 5, 2009, Pages 860-866

  Santos, Raul D ^a   Waters, David D ^b   Tarasenko, Lisa ^c   Messig, Michael ^c   Jukema, J Wouter ^d   Ferrières, Jean ^e   Verdejo, Juan ^f   Chiang, Cheng Wen ^g  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PFIZER INC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CHU RANGUEIL   (France)

^f INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEX DIFFERENCE; SMOKING; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 70350233482     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.08.009     Document Type: Article

References (29)

1. Lopez A.D., Mathers C.D., Ezzati M., et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367 (2006) 1747-1757
2. Pilote L., Dasgupta K., Guru V., et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 176 (2007) S1-S44
3. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
4. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 (2003) 1601-1610
5. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
6. Genest J., Frohlich J., Fodor G., et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ 169 (2003) 921-924
7. Schrott H.G., Bittner V., Vittinghoff E., et al. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. JAMA 277 (1997) 1281-1286
8. Mosca L., Merz N.B., Blumenthal R.S., et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 111 (2005) 488-493
9. Chou A.F., Scholle S.H., Weisman C.S., et al. Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 17 (2007) 120-130
10. Pearson T.A., Laurora I., Chu H., et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
11. Waters D.D., Brotons C., Chiang C.W., et al. The Lipid Treatment Assessment Project (L-TAP) 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation 120 (2009) 28-34
12. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
13. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
14. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., et al. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 109 (2004) 433-438
15. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
16. Yan A.T., Yan R.T., Tam M., et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 119 (2006) 678-683
17. Ansell B.J., Fonarow G.C., Maki K.C., et al. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. Am Heart J 152 (2006) 976-981
18. Nag S.S., Daniel G.W., Bullano M.F., et al. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. J Manag Care Pharm 13 (2007) 652-663
19. Cho L., Hoogwerf B., Huang J., et al. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health (Larchmt) 17 (2008) 515-521
20. Caspard H., Chan A.K., and Walker A.M. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 27 (2005) 1639-1646
21. Mosca L., Mochari H., Christian A., et al. National study of women's awareness, preventive action, and barriers to cardiovascular health. Circulation 113 (2006) 525-534
22. Cullen M.W., Stein J.H., Gagnon R., et al. National improvements in low-density lipoprotein cholesterol management in individuals at high coronary risk: National Health and Nutrition Examination Survey, 1999 to 2002. Am Heart J 156 (2008) 284-291
23. McPherson R., Angus C., Murray P., et al. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease: the Women's Atorvastatin Trial on Cholesterol (WATCH). Am Heart J 141 (2001) 949-956
24. Maeda K., Noguchi Y., and Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 37 (2003) 283-290
25. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785
26. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 (2007) 1301-1310
27. Kastelein J.J., van der Steeg W.A., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 117 (2008) 3002-3009
28. Daviglus M.L., Stamler J., Pirzada A., et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA 292 (2004) 1588-1592
29. Kotseva K., Stagmo M., De Bacquer D., et al. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 197 (2008) 710-717